A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice

Primary Care Psychiatry

Volumn 4, Issue 3, 1998, Pages 127-132

  McPartlin, G M ^a   Reynolds, A ^b   Andersen, C ^c   Casoy, J ^c  

^a St Triduanas Medical Practice   (United Kingdom)

^b PFIZER INC   (United States)

^c Wyeth Ayerst International   (United States)

Author keywords

General practice; Major depression; Paroxetine; Venlafaxine XR

Indexed keywords

PAROXETINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENERAL PRACTICE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; OUTPATIENT CARE; PRIORITY JOURNAL; SOMNOLENCE; SWEATING; UNITED KINGDOM; VERTIGO; VOMITING; XEROSTOMIA;

EID: 0031766671     PISSN: 13552570     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Muth EA, Haskins JT, Moyer JA, Husbands GEM, Nielson T, Sigg EB. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethylcyclohexanol derivative. Biochem Pharmacol 1986; 35:4493-4497.
2. Dierick M, Ravizza L, Realini R, Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatr 1996; 20:57-71.
3. Tylee A, Beaumont G, Bowden M, Reynolds A. A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe depression in general practice. Prim Care Psychiatr 1997; 3:51-58.
4. Lecrubier Y, Bourin M, Moon CAL, Schifano F, Blanchard C, Danjou P, Hackett D. Efficacy of venlafaxine in depressive illness in general practice. Acta Pychiatr Scand 1997;-95:485-493.
5. Troy SM, Parker VD, Fruncillo RJ, Chiang ST. The pharmacokinetics of venlafaxine when given in a twice-daily regimen. J Clin Pharmacol 1995; 35:404-409.
6. Troy SM, DiLea C, Martin PT, Leister CA, Fruncillo RJ, Chiang ST. Pharmacokinetics of once daily venlafaxine extended release (XR) in healthy volunteers. Curr Ther Res 1997; 58:504-514.
7. Troy SM, DiLea C, Martin PT, Rosen AS, Fruncillo RJ, Chiang ST. Bioavailability of once-daily venlafaxine extended release (XR) compared with the immediate release formulation in healthy adult volunteers. Curr Ther Res 1997; 58:492-503.
8. Cunningham LA, for the Venlafaxine XR 208 Study Group. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release in outpatients with major depression. Ann Clin Psychiatr 1997; 9:157-164.
9. Thase ME, for the Venlafaxine XR 209 Study Group. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. J Clin Psychiatr 1997; 58:393-398.
10. Hackett D, for the Venlafaxine XR Study Group. Tolerability of a once-daily formulation of venlafaxine. Biol Psychiatr 1997; 42:2445.
11. Rudolph R, for the Venlafaxine XR 211 Study Group. Efficacy and tolerability of once-daily venlafaxine XR vs. fluoxetine and placebo in depressed patients. Eur Neuropsychopharmacol 1997; 7(Suppl. 2):S168.
12. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatr 1979; 134:382-389.
13. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatr 1960; 23:56-62.
14. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, Maryland: National Institutes of Mental Health, 1976. Department of Health Education and Welfare Publication No. (ADM) 76-338.
15. Lecable P, Letzelter J-M, Lichtblau E, Prak H, De Ruiter F, Bruers Y, Hackett D. An open label evaluation of the clinical acceptability of venlafaxine for general use as an antidepressant. Prim Care Psychiatr 1995; 1:119-125.
16. Salinas E, for the Venlafaxine XR 367 Study Group. Dose-response effects of once-daily extended release (XR) venlafaxine in outpatients with major depression. Biol Psychiatr 1997; 42:2445.
17. Salinas E, for the Venlafaxine XR 367 Study Group. Once-daily extended release (XR) venlafaxine and paroxetine in outpatients with major depression. Biol Psychiatr 1997; 42:2445.
18. Benkert O, Szegedi A, Wetzel H, Staab HJ, Meister WJ Philipp M. Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed patients with inadequate treatment response. Acta Psychiatr Scand 1997; 95:288-296.
19. Dunner DL, Dunbar GC. Optimal dose regimen for paroxetine. J Clin Psychiatr 1992; 53(Suppl.):21-26.
20. Addis A, Iskedjian M, Mittmann N, Einarson TR. Meta-analysis of the treatment of major depressive disorders. Pharmacoepidemiol Drug Safety 1997; 6(Suppl. 2):S45.
21. Einarson TR, Addis A, Iskedjian M. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. Pharmacoeconomics 1997; 12(pt 2):286-296.